Skip to main content

Table 4 Final Adjusted Logistic Model of negative conversion within 28 days

From: Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study

Variable

Odds ratio

95% Confidence interval

P value

Age (per 1 year increase)

0.985

(0.960–1.011)

0.257

Male gender

1.208

(0.558–2.613)

0.632

Delayed admission ≥ 3 days (yes vs. no)

1.198

(0.527–2.726)

0.666

Lower respiratory symptom (yes vs. no)

0.166

(0.061–0.454)

 < 0.001

Neurological diseases (yes vs. no)

4.818

(0.953–24.352)

0.057

Antiviral agent (use vs. non-use)

3.049

(1.128–8.243)

0.028